Savara Inc
General ticker "SVRA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $715.6M
Savara Inc does not follow the US Stock Market performance with the rate: -20.5%.
Estimated limits based on current volatility of 3.3%: low 3.09$, high 3.30$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.46$, 7.46$]
- 2024-12-30 to 2025-12-30 estimated range: [3.08$, 6.79$]
Financial Metrics affecting the SVRA estimates:
- Negative: Non-GAAP EPS, $ of -0.33 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -6.82 <= 2.35
- Negative: negative Net income
- Positive: -0.96 < Investing cash flow per share, $ of -0.35
Short-term SVRA quotes
Long-term SVRA plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $41.48MM | $38.84MM | $60.01MM |
| Operating Income | $-41.48MM | $-38.84MM | $-60.01MM |
| Non-Operating Income | $-3.07MM | $1.38MM | $5.31MM |
| Interest Expense | $2.28MM | $0.09MM | $0.00MM |
| R&D Expense | $28.99MM | $27.88MM | $44.26MM |
| Income(Loss) | $-44.55MM | $-37.46MM | $-54.70MM |
| Profit(Loss) | $-44.55MM | $-37.46MM | $-54.70MM |
| Stockholders Equity | $144.50MM | $107.78MM | $140.37MM |
| Inventory | $1.14MM | $2.05MM | $0.00MM |
| Assets | $176.60MM | $139.78MM | $177.56MM |
| Operating Cash Flow | $-40.08MM | $-34.55MM | $-51.06MM |
| Capital expenditure | $0.06MM | $0.01MM | $0.30MM |
| Investing Cash Flow | $-69.46MM | $52.65MM | $-57.12MM |
| Financing Cash Flow | $120.81MM | $0.09MM | $82.78MM |
| Earnings Per Share* | $-0.34 | $-0.25 | $-0.33 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.